Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

DALLAS & PHILADELPHIA–(BUSINESS WIRE)–Peloton Therapeutics Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities, presented preclinical data on its lead investigational candidate, PT2385, at the American Association for Cancer Research Annual Meeting in Philadelphia, PA. PT2385 is the first clinical stage antagonist of hypoxia inducible […]

Read More »

Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease

Baxter International Inc. today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of Distinction during an […]

Read More »

ReNeuron stem cell therapy shows long-term promise for stroke

A pioneering stem cell treatment for patients disabled by stroke has continued to show long-term promise in a clinical trial, the British biotech company behind the project said on Friday. News that two-year follow-up data from a small Phase I study showed improvements in limb function with no worrying safety issues lifted shares in ReNeuron […]

Read More »

Obesity link to prostate cancer may vary by race

Obesity may be partly responsible for higher rates of prostate cancer observed among African American men, suggests a new U.S. study. The links between obesity and prostate cancer among different races is complex, researchers say, but if emphasis is put on keeping people at a healthy weight, the excess burden of this cancer among African […]

Read More »

Athersys stroke treatment fails study, shares slide

Athersys Inc’s stem-cell therapy, its only product to reach human trials, failed a mid-stage study testing it as a treatment for a type of stroke, wiping off more than 40 percent of the company’s market value. Data showed on Friday that patients given the therapy, MultiStem, did not show a significant difference from those given […]

Read More »

AstraZeneca lung cancer drug delays disease by more than a year

An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday. AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild […]

Read More »

Real World Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

AstraZeneca today presented results from two key studies showing the effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation status in newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) in clinical practice.[1],[2] Data from the studies – ASSESS and IGNITE – were reported at the European Lung […]

Read More »

ThromboGenics and VIB Form New Company to Research Roche-Rejected Cancer Drug

ThromboGenics NV (TBGNF), a biopharmaceutical company based in Leuven, Belgium, announced that it is teaming up with VIB, a life sciences institute in Flanders (Belgium), to found Oncurious NV, an oncology company.  Oncurious will focus on developing TB-403 for the treatment of pediatric brain tumors. TB-403 is a monoclonal antibody that opposes placental growth factor (PIGF). PIGF is observed in several […]

Read More »

FDA panel votes in favor of Medicines Co’s blood clot preventer

The Medicines Co’s intravenous blood clot preventer can be used in angioplasty procedures, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 9-2 to support the approval of the once-rejected injection, cangrelor, for use in some patients undergoing angioplasty, a procedure to widen narrowed or clogged coronary […]

Read More »

Snoring, apnea linked to earlier memory decline in elderly

Older people who have sleep apnea, which can be marked by heavy snoring, tend to begin experiencing cognitive decline about ten years earlier than those without the disorder, or those who use a breathing machine to treat their apnea, according to a new U.S. study. Among older people who developed mild cognitive impairment or Alzheimer’s […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom